Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Research & Development (2020 - 2023)

Terns Pharmaceuticals' Research & Development history spans 4 years, with the latest figure at $63.5 million for Q4 2023.

  • For Q4 2023, Research & Development rose 69.7% year-over-year to $63.5 million; the TTM value through Dec 2023 reached $63.5 million, up 60.28%, while the annual FY2025 figure was $77.9 million, 11.09% up from the prior year.
  • Research & Development reached $63.5 million in Q4 2023 per TERN's latest filing, up from $37.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $63.5 million in Q4 2023 to a low of $2.2 million in Q3 2022.
  • Average Research & Development over 4 years is $14.8 million, with a median of $7.6 million recorded in 2020.
  • The largest YoY upside for Research & Development was 295.44% in 2022 against a maximum downside of 69.24% in 2022.
  • A 4-year view of Research & Development shows it stood at $7.8 million in 2020, then increased by 21.78% to $9.5 million in 2021, then soared by 295.44% to $37.4 million in 2022, then surged by 69.7% to $63.5 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Research & Development are $63.5 million (Q4 2023), $37.4 million (Q4 2022), and $2.2 million (Q3 2022).